OncoMed’s demcizumab fails to meet primary endpoint in pancreatic cancer trial
OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel…
Read More...
Read More...
